Core Viewpoint - Nanjing Weilizhi Bio-Technology Co., Ltd. announced the results of its global offering, with significant oversubscription in the Hong Kong public offering and a planned listing on the Hong Kong Stock Exchange on July 25, 2025 [1][2]. Group 1: Offering Details - The Hong Kong public offering was oversubscribed by 3,494.78 times, while the international offering had a subscription rate of 40.78 times [1][2]. - The final issue price was set at HKD 35.00 per share, at the upper limit of the price range of HKD 31.60 to HKD 35.00 [1]. - The total number of shares issued was 36,862,500 H-shares, with 16,027,200 shares allocated for the Hong Kong offering and 20,835,300 shares for the international offering [1]. Group 2: Fundraising and Allocation - The total amount raised, after accounting for estimated listing expenses of HKD 110 million, was HKD 1.18 billion [1]. - A total of 12,821,700 shares were reallocated from the international offering to the Hong Kong public offering due to the oversubscription, resulting in 43.48% of shares allocated to the Hong Kong offering and 56.52% to the international offering [2]. - Seventeen cornerstone investors participated, receiving a total of 15,474,500 shares, which accounted for 41.98% of the offering shares and 8.00% of the total shares post-offering [2].
维立志博-B(9887)认购倍数超3000倍,拟于2025年7月25日上市